OSE Immunotherapeutics SA (EPA:OSE)

Market Cap	108.97M
Revenue (ttm)	83.44M
Net Income (ttm)	37.45M
Shares Out	22.42M
EPS (ttm)	1.46
PE Ratio	3.33
Forward PE	5.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,656
Average Volume	77,036
Open	4.860
Previous Close	4.860
Day's Range	4.742 - 4.910
52-Week Range	4.420 - 7.870
Beta	0.61
RSI	32.54
Earnings Date	Dec 24, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 64
• Stock Exchange: Euronext Paris
• Ticker Symbol: OSE